| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| DiaMedica Therapeutics Inc. | Director | Voting Common Shares, no par value per share | 59.9K | $168K | $2.80 | Jun 1, 2024 | Direct |
| DiaMedica Therapeutics Inc. | Director | Stock Option (right to buy) | 28.5K | Jun 1, 2024 | Direct | ||
| Trillium Therapeutics Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 0 | Nov 17, 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| DMAC | DiaMedica Therapeutics Inc. | Jun 1, 2024 | 1 | $0 | 4 | Jun 3, 2024 | Director |
| DMAC | DiaMedica Therapeutics Inc. | Jan 2, 2024 | 1 | $60K | 4 | Jan 2, 2024 | Director |
| DMAC | DiaMedica Therapeutics Inc. | Jun 1, 2023 | 1 | $0 | 4 | Jun 2, 2023 | Director |
| DMAC | DiaMedica Therapeutics Inc. | Jun 1, 2022 | 1 | $0 | 4 | Jun 2, 2022 | Director |
| DMAC | DiaMedica Therapeutics Inc. | Jan 3, 2022 | 1 | $60K | 4 | Jan 3, 2022 | Director |
| TRIL | Trillium Therapeutics Inc. | Nov 17, 2021 | 8 | $0 | 4 | Nov 19, 2021 | Chief Financial Officer |
| DMAC | DiaMedica Therapeutics Inc. | Jul 15, 2021 | 1 | $0 | 4 | Jul 16, 2021 | Director |